The ventral tegmental area (VTA), an important source of dopamine, regulates goal-and reward-directed and social behaviors, wakefulness and sleep. Hyperactivation of dopamine neurons generates behavioral pathologies. But any roles of non-dopamine VTA neurons in psychiatric illness have been little explored. Lesioning or chemogenetically inhibiting VTA GABAergic (VTA Vgat ) neurons generated persistent wakefulness with mania-like qualities: locomotor activity was increased; sensitivity to D-amphetamine was heightened; immobility times decreased on the tail suspension and forced swim tests; and sucrose preference increased. Furthermore, after sleep deprivation, mice with lesioned VTA Vgat neurons did not catch up on the lost NREM sleep, even though they were starting from an already highly sleepdeprived baseline, suggesting that the sleep homeostasis process was bypassed. The manialike behaviors, including the sleep loss, were reversed by the mood-stabilizing drug valproate, and re-emerged when valproate treatment was stopped. Lithium salts, however, had no effect.
Introduction
During the mania phase of bipolar disorder, patients sleep little and have elevated mood (e.g. increased energy and hyperactivity, impulsivity, decreased depression) [1] [2] [3] [4] [5] . In mice, pathological hyperactivity and elevated mood can be generated by various gene mutations and deletions: e.g. ClockD19 6 , REV-erba 7 , ErbB4 tyrosine kinase deletion in noradrenergic locus ceruleus cells 8 , GSK-3b overexpression 9 , dopamine transporter knockdown 10, 11 , SHANK2 knockout 12 , SHANK3 overexpression 13 , ANK3 disruptions 14 , ionotropic glutamate/AMPA receptor GluR1 knockout 15 , ionotropic glutamate/kainate GluR6 knockout 16 , phospholipase cg1 8 , glutamate-cysteine ligase modifier unit knockout 17 , and the Na/K-ATPase a3 Myshkin (Myk/+) mutation [18] [19] [20] . Some of these gene manipulations alter excitation-inhibition (E-I) balance 8, 13, 15, 16, 21 , and/or elevate catecholamines 6-8, 10, 22 , suggesting common themes that could underlie the emergence of some types of mania.
Both these themes come together in the ventral tegmental area (VTA). The VTA an important source of dopamine, regulates goal-and reward-directed and social behaviors 23, 24 , as well as wakefulness and sleep [25] [26] [27] . Exciting VTA dopamine neurons with well-chosen rhythms can produce mania-like behaviors in the day and euthymia at night 28 . In addition to dopamine neurons, there is a rich heterogeneity of glutamate and GABA neurons in the different anatomical subdomains of the VTA, and neurotransmitter co-release (e.g. dopamineglutamate, GABA-glutamate, GABA-dopamine) from VTA neurons is common 23, [29] [30] [31] .
For this paper, we focus on the midline VTA, which contains GABA (VTA Vgat ) and glutamate/nitric oxide synthase (VTA Vglut2 ) neurons 23, 32, 33 . These VTA Vgat and VTA Vglut2/NOS1 neurons inhibit and excite, respectively, the dopamine cells, but also, by projecting out of the VTA, exert effects independent of dopamine 23 . The VTA Vgat neurons co-release GABA and glutamate 31 , but the majority of these VTA neurons' actions locally are GABAergic 26 . Locally they mostly inhibit VTA Vglut2 , VTA DA and VTA Vglut2/DA cells, but also elicit a small number of pure excitatory responses 26 . Chemogenetic inhibition and chronic lesion of midline VTA Vgat neurons causes sustained wakefulness 26, 27 , and excitation of VTA Vglut2 cells and VTA dopamine cells also causes wakefulness 26 25 . VTA Vgat neurons limit arousal by inhibiting dopamine neurons and via projections to the lateral hypothalamus (LH) 26 ; VTA Vglut2 neurons produce wakefulness, also independently of dopamine, by projecting to the LH and nucleus accumbens 26 .
Here, we characterize the type of wakefulness produced by inhibiting or lesioning the VTA Vgat neurons or exciting VTA Vglut2 neurons. We find that the wakefulness induced by diminishing or removing VTA Vgat neuron inhibition contains behavioral endophenotypes that are mania-like, and are treatable with valproate, although not with lithium. On the other hand, the extended but quiet wakefulness produced by activating midline VTA Vglut2 neurons has no endophenotypes characteristic of mania. We suggest that the mania-like symptoms resulting from diminished VTA Vgat function are generated by changing the E-I balance in both the VTA and the LH.
Material & Methods
Mice: All experiments were performed in accordance with the UK Home Office Animal Procedures Act (1986); all procedures were approved by the Imperial College Ethical Review Committee and the Ethics Committee for Animal Experimentation of Xijing Hospital, Xi'an, and were conducted according to the Guidelines for Animal Experimentation of the Chinese Council institutes. The following strains of mice were used: Vgat-ires-Cre: Slc32a1 tm2(cre)Lowl /J kindly provided by B.B. Lowell, JAX stock 016962 34 ; Vglut2-ires-Cre: Slc17a6 tm2(cre)Lowl /J, kindly provided by B.B. Lowell, JAX stock 016963 34 . Mice were maintained on a 12 hr:12 hr light:dark cycle at constant temperature and humidity with ad libitum food and water.
AAV: pAAV-hSyn-DIO-hM4Di-mCherry, pAAV-hSyn-DIO-hM3Dq-mCherry and pAAV-hSyn-
DIO-mCherry were gifts from Bryan L. Roth (Addgene plasmid 44362, 44361 and 50459) 35 ;
pAAV-EF1a-DIO-taCASP3-TEV was a gift from Nirao Shah (Addgene plasmid 45580) 36 ; we packaged the transgenes into AAV capsids (capsid serotype 1/2) in house as described previously 37, 38 . rAAV2/9-EF1a-DIO-eNpHR3.0-mCherry was packaged by BrainVTA (Wuhan, China).
Surgery:
Mice were anesthetized with 2% isoflurane in oxygen by inhalation and received buprenorphine (0.1 mg/kg) and carprofen (5 mg/kg) injections, and then placed on a stereotaxic frame (Angle Two, Leica Microsystems, Milton Keynes, Buckinghamshire, UK).
The AAV was injected through a stainless steel 33-gauge/15mm/PST3 internal cannula (Hamilton) attached to a 10 µl Hamilton syringe, at a rate of 0.1 µl min −1 . For the AAV injections, virus was bilaterally injected into the VTA, 50 nl for each side of the VTA. The injection coordinates were VTA: (ML = ±0.35 mm, AP = -3.52 mm, DV = -4.25 mm). After injection, the cannula was left at the injection site for 5 min and then slowly pulled out. After injections, mice that were to undergo the sleep experiments were implanted with 3 gold-plated miniature screw electrodes (-1.5 mm Bregma, +1.5 mm midline; +1.5 mm Bregma, -1.5 mm midline; -1 mm Lambda, 0 mm midline -reference electrode) with two EMG wire (AS634, Cooner Wire, CA).
The EMG electrodes were inserted between the neck musculature. The EEG-EMG device Drug treatments: For all chemogenetic and optogenetic experiments, mice were split into random groups that received either saline or CNO injection or with or without opto-stimulation.
For dopamine antagonists injection, mice were split into random groups that received either vehicle or antagonists injection. For acute treatments with lithium or valproate, mice were received vehicle injection and behaviors (locomotion and tail-suspension) were tested, and after 1-2 week, same group of mice were received lithium or valproate injection. For acute valproate treatment with sleep experiment, mice were split into two random groups that received vehicle injection or valproate injection, and 24 hour sleep were recorded. For the Li-H2O treatment, mice were first placed with normal water, and behaviors were tested, and same group of mice were placed with Li-H2O for 2 weeks. Chemogenetics: Clozapine-N-oxide (CNO) (C0832, Sigma-Aldrich, dissolved in saline, 1 mg/kg) or saline was injected i.p. 30 minutes before the start of the behavioral tests. For VTA Vgat -hM4Di mice or VTA Vglut2 -hM3Dq mice, CNO or saline was injected during the "lights off" active phase. 1 µl CNO (5 mg/kg) was infused into the LH through the guide cannula at a rate of 0.1 µl min −1 with an injector needle (33-gauge, Hamilton) D-amphetamine: D-Amphetamine (2813/100, Tocris Bioscience, dissolved in saline, 2 mg/kg) or saline was injected i.p. into the mice 13, 19 , and the mice were assessed directly after Damphetamine injection.
Valproate and lithium: Sodium valproate (2815, TOCRIS, dissolved in saline, 200 mg/kg), LiCl (Sigma-Aldrich, dissolved in saline, 100 mg/kg) or saline (vehicle) was injected i.p. into the mice. Valproate or LiCl treatments were as previously reported 13, 39 : valproate or LiCl were injected 3 times (10:00, 14:00 and 17:00) one day before the behavioral assays; and during the day of the behavioral assay, valproate or LiCl was injected 2 times (10:00, 14:00).
Locomotion or tail-suspension tests were performed 30 min after injection (14:30) . After the locomotion or tail-suspension tests (see below), mice received a final valproate injection (17:00), and then the 24 hour sleep-wake recordings were then performed (see section "EEG analysis, sleep-wake behavior and sleep deprivation"). For the Li-H2O treatment, mice were treated with LiCl in drinking water (300 mg/L) for 2 weeks.
Dopamine receptor antagonists:
Dopamine antagonists SCH-23390 (0.03 mg/kg, dissolved in saline) and raclopride (1 mg/kg, dissolved in saline), for D1 and D2/D3 receptors respectively, were injected serially i.p. 30 minutes before the behavioral tests.
Timing of behavioral tests: All behavioral tests (see below) took place during the "lights off"
phase of the light-dark cycle, when the mice were most active, except for the sleep deprivation experiments (see section "EEG analysis, sleep-wake behavior and sleep deprivation").
Locomotor activity:
For chemogenetic experiments, the mice were received saline or CNO injection, the locomotor activity was detected 30 min after injection, and 1-2 week later, the same mice were received CNO or saline injection, and the locomotor activity was detected 30 min after injection. For D-Amphetamine experiments, mice were first put into the open field for 30 min, and the mice were received vehicle or amphetamine injection. The locomotor activity was detected straight after injection for 1 hour. The locomotor activity was detected in an activity test chamber (Med Associates, Inc) with an ANY-maze video tracking system (FUJIFILM co.), and measured by ANY-maze software (Stoelting Co. US.).
Home cage activity:
Mice were habituated in the cage for 24 h, and the activities were recorded by video tracking system for 1 h, and measured by ANY-maze software (Stoelting Co. US.).
Tail-suspension test (TST):
The TST was performed as described 13 . After a habituation period in the test room, mice were suspended 60 cm above the floor by their tails by taping the tail tip. Behaviors were video recorded and blindly scored manually and measured by ANYmaze software (Stoelting Co. US.).
Forced swimming test (FST):
Mice were placed in a borosilicate glass cylinder (5L, 18 cm diameter, 27 cm high) filled with water (25 °C, water depth 14 cm) for 6 min. The immobility time during the last 4 min was manually measured. Immobility time was defined as the time spent without any movements except for a single limb paddling to maintain flotation.
Sucrose preference test (SPT):
Mice were habituated to a dual delivery system (one bottle with water and one bottle with 1% sucrose) for 3 days. Sucrose preference was then assessed over 3 consecutive days. For the chemogenetic experiments, animals were water-restricted overnight before saline or CNO injection. 30 min after saline or CNO injection, the mice were given free access to the 2-water delivery system for 4 hours. Sucrose preference (%) was calculated as (weight of sucrose consumed) / (weight of water consumed + weight of sucrose consumed) × 100%.
EEG analysis, sleep-wake behavior and sleep deprivation:
EEG and EMG signals were recorded using Neurologger 2A devices 26, 40 . NREM sleep and wake states were automatically classified using a sleep analysis software Spike2 and manually scored. The sleep deprivation protocol was as described previously 41 . At the start of 'lights on' sleep period, mice fitted with Neurologgers were put into novel cages, and at one-hour intervals, novel objects were introduced. After 5 hours sleep deprivation, mice were then put back into their home cages for 19 hours. In total, 24 hour sleep-wake state were recorded. For the sleep experiments with dopamine receptor antagonists, mice were given SCH-23390 (0.03 mg/kg) and raclopride (2 mg/kg) injections in the middle of the 'lights off' active period.
Optogenetic stimulation: For the optogenetic behavioral experiments, a fiber patch cord was connected to the laser generator, and dual optic fibers were connected to the fiber patch through a rotary joint (ThinkerTech Nanjing BioScience Inc. China.). Before the experiments, a monofiberoptic cannula was connected to the fiber patch cord. VTA Vgat -eNpHR-mCherry®LH mice were bilaterally opto-stimulated (20 Hz, 0.5 s duration with 0.5 s interval, 593 nm, 20 μW) in the LH during the "lights off" phase. The stimulation was given for the duration of the behavioral tests.
Immunohistochemistry: These procedures were carried as described previously 26 
Results

Chemogenetic inhibition or lesioning of VTA Vgat neurons produces increased locomotor activity and sensitivity to amphetamine
We delivered AAV-DIO-hM4Di-mCherry into the VTA of Vgat-ires-cre mice to express hM4Di-mCherry (an inhibitory receptor activated by the CNO ligand) specifically in VTA Vgat neurons to generate VTA Vgat -hM4Di mice (Figure 1a ) 26 . As previously 26 (Figure 1d ; Supplementary Figure 1b ). VTA Vgat -CASP3 mice were also hyperactive in their home cages ( Supplementary Figure 1c) . Notably, the hyperlocomotion of the VTA Vgat -CASP3 mice was long-term, as seen when the mice were retested in the open field four months post lesion ( Supplementary Figure 1d) .
Mice suggested to have mania-like characteristics, or patients with bipolar-related mania, are hypersensitive to D-amphetamine 13, 19 , whereas mice and patients posited to have an attention deficit hyperactivity (ADHD)-like disorder become less active with D-amphetamine 42, 43 .
Treating CNO-injected VTA Vgat -hM4Di mice and VTA Vgat -CASP3 mice with D-amphetamine significantly increased their locomotion speed above their high baseline speed, and increased the distance travelled (Figure 1e, f ), suggesting that both groups of mice (VTA Vgat -CASP3 and CNO-injected VTA Vgat -hM4Di mice) were not ADHD-like.
Acute inhibition or chronic lesioning of VTA Vgat neurons elevates mood
We assessed mood-related behaviors using the tail-suspension test (TST), the forced swimming test (FST), and the sucrose preference test (SPT). During the TST, the immobility times of CNO-injected VTA Vgat -hM4Di mice and VTA Vgat -CASP3 mice were greatly decreased compared with saline-injected VTA Vgat -hM4Di control mice and VTA Vgat -mCherry (Figure 2a,   b ). Both CNO-injected VTA Vgat -hM4Di mice and VTA Vgat -CASP3 mice also had decreased immobility times during the FST compared with saline-injected or VTA Vgat -mCherry controls (Figure 2c, d) . This could suggest that reducing VTA Vgat neuronal output, by either chemogenetic inhibition or lesioning, produces less depressive-like behaviors. In addition, during the SPT, CNO-injected VTA Vgat -hM4Di mice and VTA Vgat -CASP3 mice consumed more sucrose than their control littermates (Figure 2e, f) , possibly indicating a raised hedonic state.
Mice with lesioned VTA Vgat neurons have less sleep need after sleep deprivation
VTA Vgat -CASP3 mice have a long-term sleep deficit 26 . To further characterize the need of VTA Vgat -CASP3 mice for sleep, we performed a sleep deprivation experiment. After sleep deprivation, there is usually a rebound in lost NREM sleep, a process termed sleep homeostasis 44 . Mice were kept awake for 5 hours with novel objects presented each hour, and were then tested to see if they caught up on lost sleep in their home cage. Control VTA Vgat -mCherry mice had rebound NREM sleep after 5 hours sleep deprivation, and thereby after 19 hours they had regained 90% of their sleep loss (Figure 2g) . Surprisingly, the VTA Vgat -CASP3 mice, despite already starting from a chronic sleep-deprived baseline, did not catch up on lost NREM sleep after 5 hours continuous sleep deprivation (Figure 2g ).
The mania-like behavior produced by lesioning VTA Vgat neurons can be pharmacologically rescued by valproate but not lithium
We assessed if lithium could treat the manic-like state of VTA Vgat -CASP3 mice ( Supplementary   Figure 2 ). However, neither acute (100 mg/kg) ( Supplementary Figure 2a Figure   2i) ). We next examined valproate (200 mg/kg) treatments (Figure 3a ). Acute injection of valproate did not affect the locomotor activity of VTA Vgat -mCherry control mice (Figure 3b ). By contrast, the hyperlocomotor activity of VTA Vgat -CASP3 mice in the open field was restored down to control levels by valproate treatment (Figure 3c ). However, 2 weeks after the acute valproate treatment was withdrawal from VTA Vgat -CASP3 mice, their hyperactivity in the open field had returned (Figure 3c) . Similarly, during the tail suspension test, valproate treatment did not affect VTA Vgat -mCherry control mice (Figure 3d ), but significantly increased the immobility time of VTA Vgat -CASP3 mice back up to control levels (Figure 3e ). Two weeks after valproate had been removed, however, the abnormally high agitation of VTA Vgat -CASP3 mice had re-emerged ( Figure 3e ).
We assessed if valproate could reduce the sustained wakefulness of VTA Vgat -CASP3 mice.
The wake time of VTA Vgat -CASP3 mice significantly decreased after treatment with valproate, whereas NREM sleep time substantially increased (Figure 3f ). VTA Vgat -CASP3 mice also have a pathological sleep architecture with fewer episodes of wake and NREM sleep, prolonged duration of each wake episode, and substantially decreased numbers of wake-NREM transitions 26 . Valproate treatment normalized the sleep-wake architecture of the VTA Vgat -CASP3 mice: the episode number ( Supplementary Figure 3a) , episode duration of wake were restored to control levels ( Supplementary Figure 3b) , as were the number of transitions between wake and NREM sleep ( Supplementary Figure 3c) .
The extended wakefulness produced by activating VTA Vglut2 neurons is not mania-like
Activating VTA Vglut2 neurons also promotes wakefulness 26 . As an internal control to eliminate the possibility that the form of artificially-induced wake in these mouse models is likely to be mania-like, we expressed the excitatory chemogenetic hM3Dq receptor in VTA Vglut2 neurons (VTA Vglut2 -hM3Dq mice; Figure 4a) 8 . Chemogenetic activation of VTA Vglut2 neurons by CNO injection did not alter the locomotor activity or distance travelled of VTA Vglut2 -hM3Dq mice compared with saline injected mice (Figure 4b ) (see also data in ref. 26 ). Moreover, the immobility time during the TST and FST did not differ between CNO injected-and saline injected VTA Vglut2 -hM3Dq mice (Figure 4c, d) . Thus, the activation of VTA Vglut2 neurons did not produce hyperactivity and mood-related deficits, suggesting a different kind of wakefulness from that generated by inhibition of VTA Vgat neurons.
VTA GABAergic neurons contribute to mania-like behaviors via dopamine signaling and projections to the LH
To examine whether the hyperactive behaviors in the VTA Vgat -CASP3 mice were produced by increased dopamine signaling, we gave a dopamine receptor antagonist mixture i.p.
(containing SCH-23390 and raclopride for D1 and D2/D3 receptors, respectively). In the openfield test, the dopamine antagonists reduced the hyperlocomotion and distance travelled of VTA Vgat -mCherry control mice (Figure 5a ), but only had a subtle effect on VTA Vgat -CASP3 mice (Figure 5a ). In the TST, dopamine receptor antagonists increased the immobility time of both VTA Vgat -mCherry control mice and VTA Vgat -CASP3 mice (Figure 5b ). However, the immobility time of VTA Vgat -CASP3 mice that received dopamine receptor antagonist injection was still significant lower than VTA Vgat -mCherry injected with dopamine receptor antagonists ( Figure   5b ). We also found that the extended wakefulness of VTA Vgat -CASP3 mice was substantially attenuated by the dopamine receptor antagonists (Supplementary Figure 4) . The above results suggest that blocking dopamine signaling partially reduces the mania-like behaviors of VTA Vgat -CASP3 mice.
VTA Vgat neurons project prominently to the LH 26 . We conducted optogenetic and chemogenetic experiments to examine if the VTA Vgat to LH projection contributes to hyperactivity and moodrelated behaviors. An AAV carrying a Cre-dependent eNpHR3.0-mCherry transgene was injected into the VTA of Vgat-ires-cre mice to express inhibitory halorhodopsin in VTA Vgat neurons to generate VTA Vgat -NpHR mice (Figure 5c ). Optic fibers were placed above the LH of VTA Vgat -NpHR mice, where dense NpHR-mCherry projections arising from the VTA Vgat cell bodies can be seen (Figure 5c ). Optogenetic inhibition of the VTA Vgat to LH projection, by activating NpHR-mCherry in the LH, elevated the locomotion of mice in the open field ( Figure   5d ), whereas it decreased the immobility times during the TST (Figure 5e ) and FST ( Figure   5f ). We confirmed this using specific chemogenetic inhibition of the VTA Vgat to LH projection.
CNO was infused directly into the LH of VTA Vgat -hM4Di mice, which expressed the inhibitory CNO receptor in VTA Vgat neurons ( Supplementary Figure 5a) . CNO infusion increased locomotion speed (Supplementary Figure 5b) , and decreased immobility time during the TST ( Supplementary Figure 5c ). These results indicate that inhibiting GABAergic tone from VTA Vgat neurons to the LH produces hyperlocomotion and less depressive-like behaviors.
Discussion
We found that endophenotypes (hyperactivity, elevated mood and reduced sleep) resembling aspects of mania could be produced by lesion or acute inhibition of GABAergic VTA Vgat neurons. In mice with lesioned or inhibited VTA Vgat neurons, D-amphetamine further increased the hyperactivity, suggesting the mania-like behavior of these mice could be the type associated with bipolar disorder in humans. The mania effects were partially blocked by D1, D2 and D3 receptor antagonists. Thus, hyperdopaminergia could originate from VTA Vgat cells failing to inhibit dopamine neurons (Fig. 5g ). VTA Vgat cells, however, are not simply VTA inhibitory interneurons that reduce dopamine's actions. Part of their actions in promoting increased movement in the FST and TST depends on their inhibitory projections to the LH.
Our results on hyperactivity produced by disinhibiting LH circuits are consistent with previous findings. In rats, repeated delivery of subthreshold stimuli (kindling) to the LH induces manialike behavior 45 . Indeed, the LH promotes physical activity and motivated behavior 46 ; LH lesions in rodents and people produce a state of wakefulness with no motion 47 . The LH contains orexin/glutamate neurons that promote arousal, motivation and energy expenditure 48 , and GABAergic neurons whose activation induces wakefulness and locomotion 46, 49, 50 . It is likely that the VTA Vgat neurons inhibit both the orexin neurons and/or the arousal/locomotorpromoting GABA neurons in the LH 26 .
Inability to sleep is one of the diagnostic criteria for the mania phase of bipolar disorder 2, 3, 51 , and certainly VTA Vgat mice sleep consistently less than control mice, such that they have 100% wakefulness during the "lights off" phase compared with control mice that take about 4 hours NREM sleep during this time 26 . Usually, the longer that wakefulness persists, the stronger the urge to sleep becomes, until sleep is inescapable. A remarkable finding is that VTA Vgat -CASP3 mice bypassed the homeostatic process of having NREM recovery sleep after sleep deprivation -they did not catch up on lost sleep in spite of already starting from a strongly sleep-deprived background. The mechanisms underlying sleep homeostasis are not well understood 44, 52, 53 . Sleep homeostasis is thought to reflect the function of sleep, (otherwise why catch up on lost sleep?), and it will be interesting to investigate if the chronic lack of sleep of VTA Vgat -CASP mice will be detrimental metabolically.
Sleep deprivation can sometimes trigger mania episodes in humans 3, 51, 54 . Consequently, an interesting question is whether the chronic sleep deprivation phenotype of VTA Vgat -CASP3 mice actually causes their mania-like symptoms. Mice chronically sleep derived with the flower pot method -the animals stay on top of a raised platform surrounded by water, and when they fall asleep, they fall into water and wake up -also develop mania-like behavior 55 . This type of sleep deprivation is, however, likely to be stressful. In the VTA Vgat -CASP3 mice, the sleepdeprivation phenotype is internally generated within the brain, and could be less stressful per se.
The mania-like behaviors of VTA Vgat -CASP3 mice, including the strong sleep loss and abnormal sleep architecture, were reversed by valproate, and re-emerged when valproate treatment was stopped. Valproate, which is FDA-approved for treating bipolar disorder, enhances GABAergic transmission and reduces action potential firing (reviewed in ref 13 ).
Lithium salts, however, had no effect in treating VTA Vgat -CASP3 mice. Lithium treatment is the first choice to treat mania episodes, although a subset of bipolar patients with rapidly cycling mania and depression phases are resistant to lithium (reviewed in ref 13 ). In most mouse models of mania, both valproate and lithium are usually effective treatments (reviewed in ref. 1 ). But similar to our results, mice with SHANK3 overexpression in the neocortex, hippocampus and basal ganglia, have mania-like symptoms treatable with valproate but not lithium 13 . It could be that the VTA Vgat -CASP3 mice and SHANK3-overexpressing mice models reflect a specific mania type.
In summary, the model based on reducing VTA Vgat neuronal function could provide further insight into the genesis of some types of mania-like behaviors. One hypothesis is that VTA Vgat neurons help set the level of mental and physical activity. Physiologically, inputs that inhibit VTA Vgat neurons will transiently intensify aspects of wakefulness useful for acute success or survival: increased activity, enhanced alertness and motivation, reduced sleep (Figure 5g ).
Taken to the extreme, however, pathology could emerge and decreased or failed inhibition from VTA Vgat neurons will produce mania-like qualities (Figure 5g ). Mann-Whitney test, *p=0.03. The light and dark shading represents the "lights on" and "lights off" phases. 
